Selection of antipsychotic agents in a psychiatric hospital based on results of CATIE study;Selección de antipsicóticos en un hospital psiquiátrico basada en los resultados del estudio CATIE

Farmacia Hospitalaria

Volumn 32, Issue 2, 2008, Pages 83-90

  Gutierrez Suela F ^a  

^a Servicio de Farmacia Sagrat Cor Serveis de Salut Mental Martorell Barcelona España   (Spain)

Author keywords

Atypical antipsychotic drug; CATIE study; Cost efficacy; Selection of antipsychotic drugs; Typical antipsychotic drug

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; FLUPHENAZINE; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; COMPARATIVE STUDY; DRUG COST; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MENTAL HOSPITAL; SCHIZOPHRENIA; ADOLESCENT; AGED; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; HOSPITALS, PSYCHIATRIC; HUMANS; MIDDLE AGED; SCHIZOPHRENIA; YOUNG ADULT;

EID: 58149391487     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-6343(08)72819-8     Document Type: Editorial

References (35)

1. Segú Tolsa JL. Elementos para la gestión del medicamento en los sistemas de salud: la visión de la microgestión. Módulo 5. Unidad Didáctica 1. Máster en Economía de la Salud y del Medicamento. Universidad Pompeu Fabra: Barcelona; 2005-2007.
2. Memoria económica. Servicio de Farmacia. Hospital Sagrat Cor, Serveis de Salut Mental: Martorell (Barcelona); 2006.
3. Catálogo de medicamentos. Consejo General de Colegios Oficiales de Farmacéuticos: Madrid; 2006.
4. Gasto en medicamentos e innovación terapéutica. Butll Groc 17 (2004) 13-18
5. Miyamoto S., Duncan G.E., Marx C.E., and Lieberman J.A. Treatment for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10 (2005) 79-104
6. Rosenheck R., Perlick D., Binghan S., Liu-Mares W., Collins J., Warren S., et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 290 (2003) 2693-2702
7. Tollefson G.D., and Sanger T.M. Negative symptoms: a path analytic approach to a double-blind, placebo-and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 154 (1997) 466-474
8. Leucht S., Walhlbeck K., Haman J., and Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361 (2003) 1581-1589
9. Davis J.M., Chen N., and Glick I.D. Ameta-analysis of the efficacy of secondgeneration antipsychotics. Arch Gen Psychiatry 60 (2003) 553-564
10. Halliday J., Farrington S., McDonald S., McEvan T., Sharkey V., and McCreadie R. Nithsdale schizophrenia surveys 23: movement disorders, 20 year review. Br J Psychiatry 181 (2002) 422-427
11. Rochon P.A., Stukel T.A., Sykora K., Gill S., Garfinkel S., Anderson G.M., et al. Atypical antipsychotics and parkinsonism. Arch Intern Med 165 (2005) 1822-1888
12. Nasrallah H.A., and Newcomer J.W. Atypical antipsychotics and metabolic dysregulation. Evaluation the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 24 (2004) S7-14
13. Lieberman J.A., Stroup T.S., McEvoy J., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005) 1209-1223
14. Ordovás J.P. Climente M. Poveda JL. Selección de medicamentos y guía farmacoterapéutica. Disponible en: htpp://sefh.interguias.com/libros/Tomo1_Cap1-3-1-1.pdf
15. Martínez-Bengoechea M.J., Viniegra A., Saiz de Rozas C., Arana A., Ibarra O., and García M.G. Criterios de selección de medicamentos para su inclusión en una guía farmacoterapéutica. Elección y ponderación. Farm Hosp 20I 1 (1996) 60-65
16. Stroup T.S., Lieberman J.A., McEvoy J., Swartz M.S., Davis S.M., Rosenheck R.A., et al. Efectiveness of olanzapine, quetiapine, risperidone and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163 (2006) 611-622
17. McEvoy J., Lieberman J., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163 (2006) 600-610
18. Rosenheck R., Leslie D., Sindelar J., Miller E.A., Lin H., Stroup T.S., et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 163 (2006) 2080-2089
19. Departamentos técnicos de los laboratorios farmacéuticos Astra Zeneca Janssen, Lilly, Merck Farma y Química y Pfizer. Barcelona; 2007.
20. Salazar M., Peralta C., and Pastor J. Tratado de psicofarmacología. Bases y aplicación clínica (2005), Médica Panamericana, Madrid
21. The Royal Pharmaceutical Society of Great Britain. Martindale: the complete drug reference. Londres; 2005.
22. Mallol J, Sureda FX, editores. Stockley. Interacciones farmacológicas. Barcelona; 2004.
23. Richard B, editor. The medical letter on drugs and therapeutics: Compendio de interacciones adversas de medicamentos. Barcelona; 2002.
24. Martínez-Bengoechea M.J., Ibánez-Carranza J.C., and Arrizabalaga M.J. Computer program for pharmacy and therapeutics Commites' drug evaluations. PWS 18 5 Suppl A (1996) A25
25. Freedman R., Carpenter W.T., Davis J.M., Goldman H.H., Tamminga C.A., and Thomas M. The cost of drugs for schizophrenia. Am J Psychiatry 163 (2006) 2029-2031
26. Peralta V. Ensayos clínicos, industria farmacéutica y práctica clínica. Bol Inf Ter de Navarra 13 4 (2005) 29-34
27. Davis J.M., and Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol 24 (2004) 192-208
28. Polsky D., Doshi J.A., Bauer M.S., and Glick H. Clinical trial-based cost-effectiveness analyses of antipsychotic use. Am J Psychiatry 163 (2006) 2047-2056
29. In: Baca E., Cervera S., Cuenca E., Giner J., Leal C., and Vallejo J. (Eds). Trastornos psicóticos (2007), Grupo Ars XXI de Comunicación, Barcelona
30. Jones P.B., Barnes T., Davies L., Dunn G., Lloyd H., Hayhurst K.P., et al. Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia. Cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 63 (2006) 1079-1087
31. Mata I, Beperet M, Madoz V, grupo Psicost. Nuevas perspectivas en la psicopatología de los trastornos esquizofrénicos. Anales del Sistema Sanitario de Navarra. 23(1). Disponible en: htpp://www.cfnavarra.es/salud/anales/textos/vol23/suple1/suple 3.html
32. Retiradas recientes de medicamentos. Butll Groc 12 (1999) 5-8
33. Sertindol vuelve al mercado español tras probar su seguridad cardiovascular. Disponible en: htpp://www.correofarmaceutico.com/rec-templating/ templates/correo_farmaceutico/cmp/viewDocument_CF.jsp
34. Leucht S., Pitschel-Walz G., Engel R., and Kissling W. Amisulpride, an usual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psyciatry 159 (2002) 180-190
35. Calderón P, Gutiérrez JR, Velasco JJ. Psiquiatría. Disponible en: htpp://sefh.interguias.com/libros/Tomo2_Cap18.pdf